

Cover Story
NCI
By Alexandria Carolan
As the likelihood of a flat budget increases for the 2024 fiscal year, NCI will have difficulty maintaining its current programs, the institute’s new director Kimryn Rathmell said in her inaugural NCI director’s report to members of the National Cancer Advisory Board Feb. 8.
In Brief


Drugs & Targets
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final















